Depomed Inc. Reaches New 12-Month High at $7.57 (DEPO)
Depomed (NASDAQ:DEPO)’s share price reached a new 52-week high on Tuesday, Stock Ratings Network.com reports. The company traded as high as $7.57 and last traded at $7.47, with a volume of 417,337 shares traded. The stock had previously closed at $7.40.
A number of research firms have recently commented on DEPO. Analysts at Zacks reiterated an “outperform” rating on shares of Depomed (NASDAQ:DEPO) in a research note to investors on Thursday, August 8th. They now have a $9.00 price target on the stock. Analysts at Roth Capital raised their price target on shares of Depomed (NASDAQ:DEPO) from $8.50 to $9.00 in a research note to investors on Tuesday, July 30th. They now have a “buy” rating on the stock.
Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $9.20.
Depomed has a 1-year low of $4.99 and a 1-year high of $7.57. The stock’s 50-day moving average is $6.83 and its 200-day moving average is $6.00. The company’s market cap is $426.3 million.
Depomed (NASDAQ:DEPO) last released its earnings data on Wednesday, August 7th. The company reported $0.01 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.05) by $0.06. The company had revenue of $30.00 million for the quarter, compared to the consensus estimate of $29.87 million. During the same quarter in the prior year, the company posted ($0.28) earnings per share. The company’s quarterly revenue was up 112.8% on a year-over-year basis. On average, analysts predict that Depomed will post $0.05 earnings per share for the current fiscal year.
Depomed, Inc (NASDAQ:DEPO) is a specialty pharmaceutical company initially focused on neurology, pain and other diseases of the central nervous system.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.